Alcon

ALC

Market cap $39.5B

79.81 USD

+0.37

0.47%

At close Updated Aug 29, 4:00 PM EDT

Pre-market

After hours

79.84

+0.03

0.04%

1 day

0.47%

5 days

-3.35%

1 month

-12.72%

3 months

-7.57%

6 months

-13.72%

Year to date

-4.36%

1 year

-17.92%

5 years

39.19%

10 years

37.51%

About: Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

Employees: 25,599

Healthcare Medical Instruments & Supplies

Funds holding %

of 7,446 funds

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

235% more call options, than puts

Call options by funds: $1.05B | Put options by funds: $312M

3.11% more ownership

Funds ownership: 50.08% [Q1] → 53.19% (+3.11%) [Q2]

3% more first-time investments, than exits

New positions opened: 67 | Existing positions closed: 65

2% less funds holding

Funds holding: 648 [Q1] → 636 (-12) [Q2]

5% less capital invested

Capital invested by funds: $24.5B [Q1] → $23.2B (-$1.3B) [Q2]

10% less repeat investments, than reductions

Existing positions increased: 202 | Existing positions reduced: 225

20% less funds holding in top 10

Funds holding in top 10: 15 [Q1] → 12 (-3) [Q2]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$78

-3% downside

Avg. target

$93

17% upside

High target

$110

38% upside

7 analyst ratings

4 positive

57%

3 neutral

43%

0 negative

Mizuho Anthony Petrone	37% upside $110	Outperform Maintained	21 Aug 2025
Morgan Stanley Patrick Wood	0% upside $80	Equal-Weight Maintained	21 Aug 2025
Baird Jeff Johnson	19% upside $95	Outperform Maintained	21 Aug 2025
JP Morgan David Adlington	2% downside $78	Neutral Downgraded	21 Aug 2025
Stifel Tom Stephan	12% upside $90	Buy Maintained	21 Aug 2025
Needham David Saxon	34% upside $107	Buy Reiterated	20 Aug 2025
Wells Fargo Larry Biegelsen	16% upside $93	Equal-Weight Reinstated	6 Aug 2025